Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update

Traws Pharma, Inc. (NASDAQ:TRAW) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 141,900 shares, an increase of 1,956.5% from the December 31st total of 6,900 shares. Based on an average daily volume of 503,100 shares, the days-to-cover ratio is currently 0.3 days. Approximately 5.2% of the company’s stock are sold short.

Traws Pharma Stock Performance

TRAW traded up $0.17 during trading hours on Tuesday, hitting $7.22. 46,434 shares of the company’s stock were exchanged, compared to its average volume of 155,822. Traws Pharma has a 1-year low of $4.06 and a 1-year high of $27.50. The firm has a 50-day moving average price of $6.68. The company has a market capitalization of $26.35 million, a PE ratio of -0.05 and a beta of 1.13.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.